RT Journal Article
SR Electronic
T1 Clinical evaluation of an application aid for less-invasive surfactant administration (LISA)
JF Archives of Disease in Childhood - Fetal and Neonatal Edition
JO Arch Dis Child Fetal Neonatal Ed
FD BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health
SP fetalneonatal-2020-319792
DO 10.1136/archdischild-2020-319792
A1 Christian Achim Maiwald
A1 Patrick Neuberger
A1 Axel R Franz
A1 Corinna Engel
A1 Matthias Vochem
A1 Christian F Poets
A1 ,
YR 2020
UL http://fn.bmj.com/content/early/2020/10/06/archdischild-2020-319792.abstract
AB Background Less-invasive surfactant administration (LISA) is increasingly used. We investigated the feasibility of a new LISA-device (Neofact®) in neonates.Design Prospective observational pilot study with open-label LISA in two tertiary neonatal intensive care units.Patients 20 infants with a gestational age of ≥26+0/7 weeks and an indication for LISA (Respiratory Severity Score (RSS)≥5 or fraction of inspired oxygen (FiO2) ≥0.30). Infants with respiratory tract malformations or unavailability of an instructed neonatologist were excluded.Main outcome measures Success of LISA, defined as laryngoscopy-confirmed intratracheal catheter position or a decrease in FiO2 by ≥0.05 or to 0.21, accompanied by an RSS decrease of ≥2; number of attempts needed for tracheal catheterisation.Results 20/57 screened infants were enrolled. Successful application occurred in 19/20 (95%). One application failed after three attempts. No device-related adverse events occurred. The median number of attempts was 2, success rate per attempt 19/31 (61%).Conclusion LISA via Neofact® appears feasible.